Pelago operates a telehealth platform that delivers cognitive behavioral therapy (CBT) and medication-assisted treatment through physician-led care teams of physicians, nurses, counselors, and coaches. Its in-app telehealth features include video and audio calling, direct-to-therapist chat, virtual therapy sessions, and structured wellness checks; the company also offers PelagoRx for confidential prescriptions. Pelago partners with employers and health-plan providers rather than selling directly to consumers and has expanded services to include adolescents. The company plans to use new funding to bring on more users, advance clinical research, and develop additional products. Since its Series B, Pelago reports an 11x revenue surge, 100% client retention, and headcount growth from 50 to 150 full-time employees. Operational scale metrics cited include more than 100 enterprise customers across industries and over 750,000 registered users as of August 2023, along with an internal study claiming a $9,367 reduction in medical claims per participant and users five times more likely to quit smoking in one year. Quit Genius is a NYC-based digital clinic treating nicotine, alcohol and opioid addictions using Medication-Assisted Treatment (MAT). The company combines virtual behavioral therapy with approved medication and connected devices. Its platform is designed to help employers tackle the cost of addiction while improving employees' lives. Quit Genius integrates with health plans, pharmacy benefit managers and wellness platforms to deliver an implementation experience. Led by co-founder and CEO Yusuf Sherwani, M.D., the company will use the funds to fuel expansion of its platform in the U.S. It raised $64M in a Series B round reported by FinSMEs. Quit Genius offers a CBT-based mobile app and a paired breath-testing device to help users quit smoking and vaping through audio sessions, animated videos and interactive exercises. The company also sells an enterprise product that charges by engagement rather than per-employee and offers a 25% quit-rate guarantee. Quit Genius reports 15 enterprise clients and independent, peer-reviewed research showing more than 60,000 people have quit smoking with a reported 53% quit rate. The startup will use the new funding to expand its digital therapeutics into alcohol and opioid addiction treatment. Quit Genius has offered free access to new sign-ups through April in response to the COVID-19 pandemic. Founders Yusuf Sherwani, Maroof Ahmed and Sarim Siddiqui are doctors who built the product to prioritize efficacy. Quit Genius is a YC-backed mobile app built by doctors that applies cognitive behavioral therapy (CBT) to help users quit smoking through audio sessions, animated videos, and interactive exercises. The company has expanded its product into modular "packs" for other addictive behaviors including alcohol, stress, motivation, and health, and plans packs for pregnancy, weight management, social pressure, and self‑esteem. Consumers are the primary focus, but Quit Genius is pursuing employer customers and has already signed an undisclosed tech giant. The team participates in scientific research: a JMIR mHealth paper found Quit Genius outperformed the NHS Smoke-free app, and an upcoming paper reported a 36% quit rate and a 59.6% reduction in cigarettes among participants. Since launch the company reports 300,000 registered users and over 20,000 people defined as smoke-free (28+ days); it aims for 100,000 smoke-free users by year‑end and will track progress publicly. Financially, the company recently closed an additional seed extension of $1.1M, bringing its seed round total to $2M. Quit Genius is a YC-backed mobile app that delivers cognitive behavioral therapy (CBT) to help users quit smoking. The program is staged and uses animated videos, audio sessions, interactive exercises, a Smoking Diary, an on-demand Coping Toolbox, and a monitored community to identify triggers and change thoughts, feelings and behaviors. The app is subscription-based: a $4/month base plan and a $15/month Quit Genius Gold tier that includes one-on-one support from a qualified Quit Coach. An independent study by researchers at Imperial College London found 36% of participants who used Quit Genius quit smoking, and non-quitters reduced cigarette consumption by 69%. The article cites the U.S. market opportunity—about 40 million smokers, 70% of whom want to quit while only 3% are successful—and notes the company plans to apply its CBT approach to other addictions and lifestyle changes. The app is available on the App Store and Google Play, and the product was developed by founders Yusuf Sherwani, Maroof Ahmed, and Sarim Siddiqui from experiences in medical-school respiratory clinics.

Total raised

$135M

Funding rounds

5

Latest round

Series C

Latest activity

Mar 2024